A potential participant has moderate Alzheimer's disease. He is 74 years old. He understands that he is at a hospital and that his wife is beside him. He can follow simple conversation. But he cannot process the complexity of a Phase II trial protocol -- the randomization, the risks of a novel disease-modifying therapy, the 18-month commitment, the lumbar punctures at months 6 and 12. He cannot provide legally valid informed consent.

His wife can. She holds durable power of attorney for healthcare decisions. She is, in the language of the regulations, his legally authorized representative. She has the legal authority to consent on his behalf.

But here is the question that separates adequate practice from excellent practice: what is his role in this conversation? Is he merely present while his wife decides? Or does he remain a participant in the truest sense -- someone whose understanding, however partial, matters, whose preferences, however incompletely expressed, deserve consideration, and whose distress, should it arise, must be taken seriously?

ICH E6(R3) is unequivocal on this point. Section 2.8.13 states that even when consent is obtained from a legally acceptable representative, "the participants should be informed about the trial in a manner that facilitates their understanding and, if capable, the participant should sign and date the informed consent form or assent form as appropriate." The participant is not a bystander. The participant is the person the entire process exists to protect.

This lesson covers how to identify who qualifies as a legally authorized representative, how to verify their authority, how to conduct the consent conversation as a triad rather than a dyad, and what additional documentation the process requires. It does not cover capacity assessment -- that is the subject of the next lesson. It does not re-teach general consent conversation techniques from Modules 2 and 3. It addresses the specific skills and knowledge required when someone other than the participant holds the pen.

A potential participant has moderate Alzheimer's disease. He is 74 years old. He understands that he is at a hospital and that his wife is beside him. He can follow simple conversation. But he cannot process the complexity of a Phase II trial protocol -- the randomization, the risks of a novel disease-modifying therapy, the 18-month commitment, the lumbar punctures at months 6 and 12. He cannot provide legally valid informed consent.

His wife can. She holds durable power of attorney for healthcare decisions. She is, in the language of the regulations, his legally authorized representative. She has the legal authority to consent on his behalf.

But here is the question that separates adequate practice from excellent practice: what is his role in this conversation? Is he merely present while his wife decides? Or does he remain a participant in the truest sense -- someone whose understanding, however partial, matters, whose preferences, however incompletely expressed, deserve consideration, and whose distress, should it arise, must be taken seriously?

ICH E6(R3) is unequivocal on this point. Section 2.8.13 states that even when consent is obtained from a legally acceptable representative, "the participants should be informed about the trial in a manner that facilitates their understanding and, if capable, the participant should sign and date the informed consent form or assent form as appropriate." The participant is not a bystander. The participant is the person the entire process exists to protect.

This lesson covers how to identify who qualifies as a legally authorized representative, how to verify their authority, how to conduct the consent conversation as a triad rather than a dyad, and what additional documentation the process requires. It does not cover capacity assessment -- that is the subject of the next lesson. It does not re-teach general consent conversation techniques from Modules 2 and 3. It addresses the specific skills and knowledge required when someone other than the participant holds the pen.